NCCN Guidelines Now Specifically Name clonoSEQ, Prefer 10^-6 MRD Sensitivity in Myeloma
ADPT has more than doubled off its 52-week low of $12 on elevated volume (1.8× avg).
Summary
The NCCN Clinical Practice Guidelines for Multiple Myeloma now include a dedicated MRD testing page (MYEL-E) and specifically name clonoSEQ as the only FDA-cleared assay for MRD assessment. The guidelines state 10^-6 sensitivity is preferred, with 10^-5 as minimum, and expand recommended testing timepoints to include annual maintenance and post-CAR T-cell therapy. This is a meaningful regulatory/clinical endorsement that could accelerate clonoSEQ adoption in community oncology practices, where NCCN guidelines heavily influence treatment decisions. The update follows Adaptive's strong Q2 results and raised MRD revenue guidance, reinforcing the company's commercial momentum. Watch for any commentary from management on expected revenue impact from this guideline change.
At the time of this announcement, ADPT was trading at $27.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $12.00 to $28.72. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.